Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2
{{output}}
Gastric cancer (GC) and esophagogastric junction cancer (EGJC) impose a severe global burden, with traditional treatments plagued by poor efficacy, high toxicity, and chemoresistance. Claudin 18.2 (CLDN18.2), a highly tissue-specific target, is abnormally over... ...
